Cullinan Share Price

Cullinan Share Price

NASDAQ: CGEM | Small Cap | Healthcare
$9.08
+$0.09 (0.94%) Last updated on 20 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Cullinan Stock Performance

Open
$9.05
Prev. Close
$8.99
Circuit Range
N/A
Day Range
$8.59 - $9.17
Year Range
$8.25 - $23.16
Volume
30,816
Average Traded
$9.02

Cullinan Share Price Today

As of 20 November 2026, Cullinan Therapeutics, Inc.'s share price is $9.08. The stock opened at $9.05, compared to its previous close of $8.99. During today's trading session, Cullinan Therapeutics, Inc.'s share price traded between $8.59 and $9.17, with an average price of $8.88. Over the past 52 weeks, the stock has recorded a high of $23.16 and a low of $8.25. In terms of performance, Cullinan Therapeutics, Inc.'s share price has declined by 44.75% over the last six months and is down 19.96% on a year-on-year basis.

Cullinan Share Price Chart

Line chart of the Cullinan price trend over the selected period. The price rose overall, ranging from 8.81 to 9.47, ending at 9.01.
$8.59$9.17
L
Show Current Price
H

Cullinan Stock Fundamentals & Key Indicators

Market Cap
$536.17M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.71
Revenue (TTM)
$0.00
Return On Equity (TTM)
-62.61%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-64.78%

Cullinan Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$29.05-$45.49-$53.70-$47.87
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-56.59%-18.05%10.86%

Cullinan Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit$111.21-$133.45-$149.39-$198.21
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-220.00%-11.94%-32.68%

Cullinan Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets61.62207.163.9986.65
Current Assets386.76414.67480.19474.47
Total Assets448.37621.82484.18561.12
Non Current Liabilities1.90.852.153.59
Current Liabilities37.7430.6528.1422.5
Total Liabilities39.6431.530.2926.09
Shareholders' Equity408.73590.33453.9535.03

Cullinan Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-175.75-145.3-134.28-126.66
Investing179.99-136.3135.81248.98
Financing1.09266.1940.75-25.93

About Cullinan

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Cullinan Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$15.22
$9.05
-39.91%
Oct 2026
$15.21
$15.06
-1.95%
Sep 2026
$21.73
$15.36
-31.85%
Aug 2026
$16.50
$22.54
+36.61%
Jul 2026
$18.05
$16.50
-9.39%
Jun 2026
$15.96
$18.21
+10.80%
May 2026
$13.10
$16.43
+26.04%
Apr 2026
$14.43
$13.04
-8.23%
Mar 2026
$15.25
$14.21
-8.32%
Feb 2026
$12.40
$15.50
+29.60%
Jan 2026
$10.49
$11.96
+15.78%
Dec 2025
$11.33
$10.33
-8.95%

Cullinan Share Price FAQs